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Abstract 
A series of chalcone-based diarylpyrazoles containing a phenylsulphone or 
carbonitrile moiety was synthesized. Thus, 3-acetylpyrazoles 6a–c and 10a–c 
were used as useful substrates in facile synthesis of functional pyrazoles 7a–f 
and 11a–f, respectively. The anti-inflammatory activity and ulcerogenic effect 
were evaluated and some of the obtained products possessed a significant anti-
inflammatory activity. 1-[1-(3-Methylphenyl)-5-phenyl-4-(phenylsulfonyl)-1H-
pyrazol-3-yl]ethanone (6b) showed a high activity when compared with 
indomethacin as reference drug with lower gastrointestinal (GI) profile. 
Furthermore, molecular docking studies were performed in order to rationalize 
the obtained biological results.  
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Introduction 
Management of inflammatory disorders involves a stepwise approach to the use of 
therapeutic agents. Relieving of pain and reduction of inflammation are urgent goals to 
reduce the severity of symptoms. A generally accepted stepwise approach to treat the 
inflammation disorders includes physical therapy, non-steroidal anti-inflammatory drugs 
(NSAIDs), disease modifying anti-rheumatic drugs (DMARDs), corticosteroids and finally, 
immunosuppressive agents [1, 2]. However, NSAIDs remain among the most widely 
prescribed drugs worldwide; they have been generally considered as inhibitors of 
cyclooxygenases (COXs) [3, 4]. Most of NSAIDs act by reducing prostaglandin 
biosynthesis through the inhibition of the COX reaction  [5]. Moreover, data have been 
accumulating through the years suggesting that NSAIDs also probably act on other targets 
to counteract pain. In spite of their beneficial action, their activity is associated with 
deleterious side effects, and continuous administration of these drugs leads to 
nephrotoxicity and gastric ulcerations. The therapeutic anti-inflammatory action of NSAIDs 
is produced by inhibition of COX-2, while the unwanted side effects arise from the 
inhibition of COX-1 activity. It is estimated that 25% of patients using NSAIDs experience 
some kind of side effect and about 5% develop serious health consequence (massive GI 
bleed, acute renal failure, etc.). Consequently, extensive research has been directed 
towards improving their pharmacological profile [6].  
Recently, a novel class of selective COX-2 inhibitors has been discovered. Among this 
class, celecoxib (Figure 1), the potent and gastrointestinal (GI) safe anti-inflammatory 
agent. It is considered a typical model of sulphonamide-based diarylpyrazole template that 
is known to selectively inhibit COX-2 [7–15]. Furthermore, several arylpyrazoles are 
available as anti-inflammatory drugs in market such as valdecoxib [16], rofecoxib  [17], 
etoricoxib [18, 19].  SC-558, diarylpyrazole derivative (Figure 1), was found to be a 
marvelous inhibitor with 1900-fold selectivity for COX-2 over COX-1. In addition, both SC-
558 and celecoxib were published, co-crystallized with the active site of COX-2, with many 
investigations about their mechanism of action and selectivity to COX-2 [20–22]. 
Celecoxib 6a–c  R = Me; R
1 = SO2-Ph; 
  X = H, 3-Me, 4-Me 
10a–f  R = Me, -CH=CH-Ph(-C6H4-OMe); 
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1 = SO2-Ph; X = H, 3-Me, 4-Me 
7a–c  R = Me; R
1 = -CN; X = H, 3-Me, 4-Me 
11a–f  R = Me, -CH=CH-Ph(-C6H4-OMe); 
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1 = -CN; X = H, 3-Me, 4-Me
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In view of the above facts and in continuation of our interest in the synthesis of bioactive 
heterocycles, especially pyrazole derivatives [23–32], we report here some di/triaryl-
pyrazoles having phenylsulphone or carbonitrile moiety (Figure 1). The anti-inflammatory 
activity of the synthesized compounds was evaluated. Moreover, molecular docking 
studies of active compounds were carried out to rationalize their activity. 
Results and Discussion 
Chemistry 
Cyclization reaction of hydrazonoyl chlorides 1a–c  with  1-phenyl-2-(phenylsulfonyl)-
ethanone (2) in ethanolic sodium ethoxide solution at room temperature furnished 
1-(5-phenyl-4-(phenylsulfonyl)-1-aryl-1H-pyrazol-3-yl)ethanones  (6a–c),  respectively 
(Scheme 1). The latter pyrazoles were reacted with benzaldehyde or 4-anisaldehyde in 
ethanol containing 10% aqueous sodium hydroxide at room temperature to afford 
chalcones  7a–f. The IR spectra of the latter chalcones showed, in each case, the 
appearance of absorption band in the region 1640–1676  cm
−1  corresponding to the 
carbonyl function. Their 
1H NMR spectra showed the disappearance of COCH3 protons 
signal and displayed the signals of olefinic protons in the aromatic region. 
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Sch. 1.   Reagents and conditions: (a) EtONa/EtOH, stirring 12 h r.t.; (b) Ar1-CHO, EtOH, 
10% NaOH, stirring 12 h, r.t. 510  E. Nassar et al.:   
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Similarly, the reaction of 3-acetyl-(1-aryl)-5-phenyl-1H-pyrazole-4-carbonitriles  (10a–c) 
with benzaldehyde or 4-anisaldehyde, under the same reaction conditions for synthesis of 
7a–f, afforded the corresponding chalcones 11a–f, respectively (Scheme 2). The structure 
of the latter chalcones was confirmed under the basis of their spectral data. For example, 
their IR spectra revealed the appearance of absorption band in the region 1662–1668 cm
−1 
due to the carbonyl group in addition to the appearance of sharp absorption peak of 
carbonitrile function around 2235 cm
−1 and their mass spectra showed, in each case, a 
peak corresponding to their molecular ion. 
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Sch. 2.   Reagents and conditions: (a) EtONa/EtOH, stirring 12 h, r.t.; (b) Ar1-CHO, 
EtOH, 10% NaOH, stirring 12 h, r.t. 
Pharmacology 
Anti-inflammatory activity 
The anti-inflammatory effect of tested compounds, meloxicam and  indomethacin, on 
carrageenan-induced edema at  3  and  6h, is depicted in Table 1.  Percent edema 
inhibition (Table 1) was calculated in regard to control group and the potency (%) was 
calculated respect to the indomethacin response. After 3h, the tested compounds 6a–c, 
7b, 7d, 10a and 11b showed a reasonable decrease in the edema size ranging between 
30.12% for compound 6c and 105.51% for the most active compound 6b. On the other 
hand, compounds 11c–f showed a weak activity in reduction of edema size after the same 
time (< 27.34 % for 11e) as shown in Table 1. After 6h, 6b was still the most potent anti-
inflammatory compound in minimizing the inflammation size with 99.82% activity. 
However, compounds  7a,  7c,  7e,  7f,  10b,  10c  and  11a  showed no inhibitory effect 
(Table 1).   Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones …511 
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Tab. 1.  Inhibitory effect of indomethacin, meloxicam and the tested compounds on 
carrageenan-induced edema of the hind paw in rats 
Group 
Before 
injection 
Edema vol. 
3 h  6 h 
Edema  
vol. 
% Edema 
inhibition 
Pot.  
(%) 
Edema 
vol. 
% Edema 
inhibition 
Pot.  
(%) 
Control  0.289 ± 
0.018 
0.475 ± 
0.012  –  0  0.475 ± 
0.012  –  0 
6a  0.243 ± 
0.014 
0.370 ± 
0.017
b  31.39  68.53  0.378 ± 
0.017  27.53  56.39 
6b  0.244 ± 
0.017 
0.340 ± 
0.018
c  48.33  105.51  0.341 ± 
0.021
b  48.74  99.82 
6c  0.256 ± 
0.011 
0.393 ± 
0.018  13.80  30.12  0.356 ± 
0.026
a  21.23  43.48 
7a  0.248 ± 
0.010 
0.437 ± 
0.015  0.00  0.00  0.447 ± 
0.014  0.00  0.00 
7b  0.249 ± 
0.009 
0.363 ± 
0.020
a  38.38  83.77  0.366 ± 
0.021
a  36.54  74.83 
7c  0.290 ± 
0.015 
0.481 ± 
0.011  0.00  0.00  0.491 ± 
0.008  0.00  0.00 
7d  0.257 ± 
0.009 
0.384 ± 
0.011
a  32.05  69.96  0.368 ± 
0.011
a  40.59  83.12 
7e  0.259 ± 
0.012 
0.448 ± 
0.006  0.00  0.00  0.457 ± 
0.021  0.00  0.00 
7f  0.260 ± 
0.010 
0.452 ± 
0.007  0.00  0.00  0.458 ± 
0.014  0.00  0.00 
10a  0.256 ± 
0.013 
0.379 ± 
0.021
a  33.31  72.70  0.365 ± 
0.017
a  41.00  83.97 
10b  0.241 ± 
0.018 
0.439 ± 
0.005  0.00  0.00  0.443 ± 
0.009  0.00  0.00 
10c  0.251 ± 
0.010 
0.447 ± 
0.009  0.00  0.00  0.438 ± 
0.004  0.00  0.00 
11a  0.248 ± 
0.009 
0.439 ± 
0.011  0.00  0.00  0.446 ± 
0.006  0.00  0.00 
11b  0.239 ± 
0.009 
0.391 ± 
0.013  17.88  39.04  0.386 ± 
0.045  20.50  41.99 
11c  0.252 ± 
0.010 
0.422 ± 
0.019  8.08  17.64  0.414 ± 
0.019  12.59  25.78 
11d  0.261 ± 
0.009 
0.451 ± 
0.018  0.00  0.00  0.438 ± 
0.020  4.94  10.11 
11e  0.253 ± 
0.016 
0.419 ± 
0.016  10.85  23.69  0.410 ± 
0.014  15.54  31.83 
11f  0.262 ± 
0.011 
0.424 ± 
0.007  12.52  27.34  0.419 ± 
0.011  15.36  31.46 
Meloxicam  0.279 ± 
0.009 
0.385 ± 
0.017
a  42.65  93.10  0.375 ± 
0.018  48.25  98.82 
Indomethacin  0.263 ± 
0.016 
0.364 ± 
0.011
b  45.81  100  0.358 ± 
0.017
a  48.83  100 
Values represent means ± SEM of six animals for each group. The potency (pot.) was calculated compared 
to the reference drug indomethacin. Statistical analysis using One-way ANOVA (Bonferroni’s multiple 
comparison test). Significance levels 
a P < 0.05; 
b P < 0.01 and 
c P < 0.001 as compared with control. 512  E. Nassar et al.:   
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From the structure activity relationship (SAR) viewpoint, the anti-inflammatory activity of 
phenylsulfonylpyrazoles such as 6a, 6c, 7b and 7d were found to be higher than that of 
carbonitrile pyrazoles except  10a  which achieved a greater  activity. Additionally, the 
introducing of chalcone moiety to pyrazole ring was found to be variable in effectiveness of 
activity. However, these results imply that the phenyl sulphone moiety and carbonyl group 
attached to the pyrazole system is an essential pharmacophore responsible for activity. 
Furthermore, changing the position of 4-methyl substituent of N-phenyl ring in 6c  to 
position 3 in 6b increased the activity. On the other hand, the phenylsulphonylpyrazoles 
that contains 4-methoxybenzylidine group, 7b and 7d, showed a higher activity while that 
with benzylidine group, 7a and 7c, have no activity. Taken together, the results of 6a-c and 
7a-f provide evidence that the structural features of arylidine moieties and changes in the 
N-aryl group significantly affects their anti-inflammatory activity. 
Ulcerogenic effects 
The most active compounds 6b,  7b,  7d  and  10a  were selected for the 
ulcerogenic study  as compared to the reference drugs  meloxicam and 
indomethacin [33]. Compound 6b showed lower ulceration (1.5) respect to meloxicam 
(1.67) or to indomethacin (3.17) while compounds 7b, and 7d  recorded ulcer 
index higher than meloxicam but still lower than indomethacin; compound 
10a showed the highest ulcer index (2.83) (Table 2). 
Tab. 2.  Ulcer index of indomethacin, meloxicam, 6b, 7b, 7d and 10a. 
Compound  Ulcer index
a 
Control  0.25 ± 0.274 
6b  1.5   ± 1.000
 
7b       2 ± 0.894
b 
7d  1.83 ± 0.983
 
10a  2.83 ± 0.753
c 
Meloxicam  1.67 ± 0.817
 
Indomethacin  3.17 ± 0.753
c 
a Values represent means ± SD (n = 6); 
Significance level b, P < 0.05; c, P < 0.01 
as compared with the respective control. 
 
Molecular docking  
The docking runs were conducted using Molsoft ICM-pro software to rationalize the 
obtained biological results. Besides, the molecular docking studies helped in 
understanding the various interactions between the ligand and enzyme active sites. An 
automated docking study was carried out using the crystal structure of COX-2 (pdb ID: 
1CX2) in which SC-558 co-crystallized as a ligand [20]. Both enzymes were submitted to 
regularization process to fit the protein model with the ideal covalent geometry of residues 
to the atom positions of a target PDB structure [34]. The regularized protein was used in 
determination of the important amino acids in ligand binding pocket (LBP) of COX-2 
enzyme.    Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones …513 
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Re-docking of the SC-558 was done to investigate its interaction with active site of COX-2 
enzyme. Binding mode of SC-558 showed the binding of bromophenyl ring in a 
hydrophobic cavity by Gly526, Leu384, Tyr385, Trp387, Met522, Phe518, Val523 and 
Ser530 interaction (Figure 2). The trifluoromethyl group was bounded in an adjacent 
pocket by Val116, Tyr355, Leu359 and Leu531. The sulphonamide group extends into a 
relatively polar region and interacts with His90, Arg513, Gln192, Leu352 and Ser353 
[20, 35]. Interactive docking using Mol table ligand was carried out for all the conformers of 
all of the tested compounds with remarked biological activity to the selected active site of 
COX-2. Each docked compound was assigned by a score according to its fitting to LBP 
and its binding mode with different amino acid residues that have a role in its biological 
activity (Table 3).  
 
Fig. 2.  Binding mode of SC- 558 with COX-2 active site. The hydrogen bonds with 
amino acid residues His90, Tyr355, Arg513, Gln192 & Ser353 represented by 
green lines. 
The interaction of 6b with COX-2 active site appeared that, sulphone function and carbonyl 
group were formed a hydrogen bonds with Tyr355, His90 and Arg513 (Figure 3). In 
addition, the acetyl group was imbedded in the hydrophobic pocket of Phe518, Ala516, 
Ser353 and Leu352. In addition, the m-methyl substituent in 6b was surrounded by a 
pocket of Gly526, Tyr385 and Trp387.  
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Tab. 3.  Docking results of SC-558 and the tested compounds with active site of COX-2.  
Cpd.  Conformational  
stack energy  
(kcal/mol) 
H-bonds  Amino acid residue(s) of H-bond(s)  
(bond length Å) 
SC-558  -88.3709  5  Arg513 (2.20), His90 (2.30), Gln192 (2.79), 
Ser353 (1.51) & Tyr355 (2.16) 
6a  −63.6787  5  Tyr355 (1.03), His90 (2.51, 2.62) & Arg513 
(1.76, 2.58) 
6b  −67.6756  5  Tyr355 (1.09), His90 (2.39, 2.50) & Arg513 
(1.82, 2.73) 
6c  −54.3336  5  Tyr355 (1.07), His90 (2.45, 2.48) & Arg513 
(1.62, 2.55) 
7b  −57.7361  3  Tyr355 (0.95), His90 (2.66) & Arg513 (2.45) 
7d  −64.2746  3  Tyr355 (1.01), His90 (2.59) & Arg513 (2.09) 
10a  −57.7051  2  Arg120 (2.61) & Tyr355 (2.21) 
11b  −52.7570  2  Arg120 (2.55) & Tyr355 (2.10) 
11c  −43.5693  3  Arg513 (2.24) & Tyr355 (1.44) 
11e  −49.9558  2  His90 (2.51) & Tyr355 (2.01) 
11f  −44.2973  3  Arg513 (2.36) & Tyr355 (1.63) 
 
 
Fig. 3.  Docking of compound 6b inside the LBP of COX-2 showing the hydrogen bonds 
(green lines) and the stacks of aryl rings.   Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones …515 
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Next, the binding mode of interaction of compound 10a overlaid with SC-558 revealed the 
same alignment with SC-558. Nevertheless, compound 10a  showed a deficient of 
sulphonamide binding mode (Figure 4). Compounds 7b and 7d gave good binding scores 
and binding modes with different amino acids in the receptor of COX-2 respect to their 
biological activity. 
 
Fig. 4.  Overlay of SC-558 (green) and 10a (orange) inside the active site of COX-2. 
Conclusion 
In conclusion, we described a facile synthesis of poly-functionally  pyrazoles. Some of 
synthesized pyrazoles showed a significant anti-inflammatory activity. 1-(5-Phenyl-
4-(phenylsulfonyl)-1-(3-tolyl)-1H-pyrazol-3-yl)ethanone (6b) possessed a high activity, 
when compared with reference drugs, with lower gastrointestinal (GI) profiles while 
compounds 7b, 7d and 10a have a moderate anti-inflammatory activity. Molecular docking 
study gave us good information about the interaction mode of sulfone-based pyrazoles 
with COX-2 active site. They have the ability to make hydrogen bonds with amino acid 
residues Tyr355, His90 and Arg513 in COX-2 active site.  
Experimental 
Chemistry 
Melting points (°C, uncorrected) were determined using a Gallenkamp melting point 
apparatus. Elemental analytical data were obtained from the microanalytical unit, Cairo 516  E. Nassar et al.:   
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University, Giza, Egypt. The IR spectra (KBr) were recorded on a PerkinElmer FT/IR 
spectrometer. At 400 MHz, the NMR spectra were recorded on a Jeol spectrometer using 
tetramethylsilane as an internal standard. 
1H and 
13C spectra were run at 400 and 100 
MHz, respectively. Splitting patterns are designated as follows: s, singlet; d, doublet; t, 
triplet; m, multiplet. Chemical shift (δ) values are given in parts per million and coupling 
constants (J) in Hertz. The mass spectra were performed using a Varian MAT CH-5 
spectrometer (70 eV). 
1-(5-Phenyl-4-(phenylsulfonyl)-1-aryl-1H-pyrazol-3-yl)ethanone (6a–c) 
1-Phenyl-2-(phenylsulfonyl)ethanone (2) (2.6 g, 10 mmol) was added to a stirred ethanolic 
sodium ethoxide solution [prepared from sodium metal (0.23 g, 10 mmol) and 50 mL of 
absolute ethanol]. After stirring for 20 min, the appropriate 2-oxo-N'-arylpropane-
hydrazonoyl chloride (1a–c) (10 mmol) was added and the reaction mixture was left to stir 
at room temperature for 12 h. Then added to cold water, the solid product was collected by 
filtration, washed with water and dried. Recrystallization from ethanol afforded pyrazoles 
6a–c. Synthesis of pyrazoles 6a and 6c, using ultrasonic, was reported earlier [36]. 
1-[1-(3-Methylphenyl)-5-phenyl-4-(phenylsulfonyl)-1H-pyrazol-3-yl]ethanone (6b) 
Pale yellow crystals, 74% yield; mp 166–168 °C; IR (KBr) νmax/cm
−1 1708 (C=O), 1610 
(C=N); 
1H NMR (DMSO-d6) δ 2.24 (s, 3H, m-CH3), 2.56 (s, 3H, -COCH3), 7.09–7.42 (m, 
9H, ArH), 7.57–7.69 (m, 3H, ArH), 7.89 (d, 2H, J = 7.92 Hz, ArH); 
13C NMR δ 21.21 (m-
CH3), 28.73 (-COCH3), 127.44, 127.92, 128.36, 129.18, 129.43, 130.25, 130.46, 131.19, 
133.83, 138.43, 139.25, 142.49, 148.37, 192.70 (-COCH3); MS m/z (%) 416 (M
+, 1.93), 
207 (100.0). Anal. Calcd for C24H20N2O3S (416.49): C, 69.21; H, 4.84; N, 6.73; S, 7.70. 
Found: C, 69.42; H, 4.93; N, 6.59; S, 7.53. 
Synthesis of chalcones 7a–f 
To a stirred solution of pyrazole 6a–c (10 mmol) and the appropriate aldehyde (10 mmol) 
in ethanol (30 mL), 10% aqueous sodium hydroxide (5 mL) was added portion-wise at 
room temperature for 10 min, the reaction mixture was further stirred for 12 h. The 
resulting solid was filtered off, washed with water, dried and crystallized from EtOH/DMF to 
afford chalcones 7a–f. 
(2E)-1-(1,5-Diphenyl-4-(phenylsulfonyl)-1H-pyrazol-3-yl)-3-phenylprop-2-en-1-one (7a) 
White powder, 79% yield; mp 186–188 °C; IR (KBr) νmax/cm
−1 1646 (C=O), 1607 (C=N); 
1H 
NMR (DMSO-d6) δ 7.38–7.90 (m, 22H, ArH); 
13C NMR δ 121.89, 124.82, 127.00, 127.70, 
127.91, 128.47, 129.53, 129.65, 129.79, 130.37, 131.22, 131,74, 133.92, 134.92, 138.59, 
142.52, 146.80, 148.95, 185.21 (-C=O); MS m/z  (%)  490  (M
+, 0.95), 207 (100). Anal. 
Calcd for C30H22N2O3S (490.57): C, 73.45; H, 4.52; N, 5.71; S, 6.54. Found: C, 73.31; H, 
4.57; N, 5.84; S, 6.42. 
(2E)-1-(1,5-Diphenyl-4-(phenylsulfonyl)-1H-pyrazol-3-yl)-3-(4-methoxyphenyl)prop-2-en-1-
one (7b) 
White powder, 62% yield; mp 176–178 °C; IR (KBr) νmax/cm
−1 1676 (C=O), 1589 (C=N); 
1H 
NMR (DMSO-d6) δ 3.82 (s, 3H, -OCH3), 7.01–7.04 (d, 2H, J = 8.8 Hz, ArH), 7.36-7.44 (m, 
11H, ArH), 7.57-7.89 (m, 8H, ArH); 
13C NMR δ 56.00 (-OCH3), 115.15, 121.78, 122.61, 
126.96, 127.30, 127.73, 127.91, 128.47, 129.51, 129.74, 130.35, 131.22, 131.54, 133.88,   Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones …517 
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138.60, 142.58, 146.93, 147.58, 149.28, 185.31 (-C=O); MS m/z (%) 521 (M
++1, 0.70), 
281 (36.82), 207 (100), 73 (41.93). Anal. Calcd for C31H24N2O4S (520.60): C, 71.52; H, 
4.65; N, 5.38; S, 6.16. Found: C, 71.35; H, 4.48; N, 5.31; S, 6.30. 
(2E)-1-[1-(3-Methylphenyl)-5-phenyl-4-(phenylsulfonyl)-1H-pyrazol-3-yl]-3-phenylprop-
2-en-1-one (7c) 
White powder, 65% yield; mp 110–112 °C; IR (KBr) νmax/cm
−1 1676 (C=O), 1610 (C=N); 
1H 
NMR (DMSO-d6) δ 2.24 (s, 3H, m-CH3), 7.14–7.88 (m, 21H, ArH); 
13C NMR δ 21.23 (m-
CH3), 123.97, 124.81, 127.42, 127.72, 127.86, 128.44, 129.19, 129.51, 129.63, 130.38, 
131.21, 131.72, 133.89, 134.67, 138.50, 139.24, 146.67, 147.69, 185.40 (-C=O); MS m/z 
(%) 504 (M
+, 6.87), 207 (100). Anal. Calcd for C31H24N2O3S (504.60): C, 73.79; H, 4.79; N, 
5.55; S, 6.35. Found: C, 73.85; H, 4.75; N, 5.47; S, 6.48. 
(2E)-3-(4-Methoxyphenyl)-1-[1-(3-methylphenyl)-5-phenyl-4-(phenylsulfonyl)-1H-pyrazol-
3-yl]prop-2-en-1-one (7d) 
White powder, 63% yield; mp 169–171 °C; IR (KBr) νmax/cm
−1 1640 (C=O), 1597 (C=N); 
1H 
NMR (DMSO-d6) δ 2.24 (s, 3H, m-CH3), 3.83 (s, 3H, -OCH3), 7.02–7.86 (m, 20H, ArH); 
13C 
NMR δ 21.23 (m-CH3), 56.01 (-OCH3), 115.15, 121.70, 122.58, 123.94, 127.30, 127.39, 
127.75, 127.85, 128.44, 129.18, 129.49, 130.33, 131.21, 131.55, 133.85, 138.51, 139.23, 
142.59, 146.81, 147.50, 149.23, 185.30 (-C=O); MS m/z (%) 534 (M
+, 2.56), 207 (100). 
Anal. Calcd for  C32H26N2O4S (534.62):  C, 71.89; H, 4.90; N, 5.24; S, 6.00.  Found:  C, 
71.77; H, 4.91; N, 5.38; S, 5.93. 
(2E)-1-[1-(4-Methylphenyl)-5-phenyl-4-(phenylsulfonyl)-1H-pyrazol-3-yl]-3-phenylprop-
2-en-1-one (7e) 
White fibers, 60% yield; mp 173–174 °C; IR (KBr) νmax/cm
−1 1642 (C=O), 1602 (C=N); 
1H 
NMR (DMSO-d6) δ 2.26 (s, 3H, p-CH3), 7.17–7.89 (m, 21H, ArH); 
13C NMR δ 21.15 (p-
CH3), 121.80, 124.86, 126.74, 127.78, 127.89, 128.47, 129.51, 129.64, 129.93, 130.34, 
131.20, 131.71, 133.88, 134.69, 136.18, 139.50, 142.56, 146.70, 147.69, 148.87, 185.22 
(-C=O); MS m/z (%) 504 (M
+, 0.57), 281 (39.65), 207 (100), 96 (24.96), 73 (45.89). Anal. 
Calcd for C31H24N2O3S (504.60): C, 73.79; H, 4.79; N, 5.55; S, 6.35. Found: C, 73.66; H, 
4.91; N, 5.42; S, 6.38. 
(2E)-3-(4-Methoxyphenyl)-1-[1-(4-methylphenyl)-5-phenyl-4-(phenylsulfonyl)-1H-pyrazol-
3-yl]prop-2-en-1-one (7f) 
White fibers, 61% yield; mp 178–180 °C; IR (KBr) νmax/cm
−1 1676 (C=O), 1593 (C=N); 
1H 
NMR (DMSO-d6) δ (s, 3H, p-CH3), 3.82 (s, 3H, -OCH3), 7.01–7.88 (m, 20H, ArH); 
13C NMR 
δ 21.23 (p-CH3), 56.00 (-OCH3), 115.15, 121.68, 122.66, 126.70, 127.32, 127.81, 127.88, 
128.47, 129.50, 129.92, 130.31, 131.20131.51, 133.85, 136.20, 139.44, 142.62, 146.82, 
147,49, 149.20, 185.32 (-C=O); MS m/z (%) 533 (M
+, 0.50), 281 (17.83), 207 (100), 73 
(29.26). Anal. Calcd for C32H26N2O4S (534.62): C, 71.89; H, 4.90; N, 5.24; S, 6.00. Found: 
C, 72.04; H, 5.06; N, 5.37; S, 5.88. 
Synthesis of pyrazoles 10a–c 
Those compounds were synthesized using the method that described for  synthesis of 
pyrazoles 6a–c using benzoylacetonitrile 8 instead of sulphone 3. pyrazoles 10a and 10c 
were described in literature [37]. 518  E. Nassar et al.:   
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3-Acetyl-1-(3-methylphenyl)-5-phenyl-1H-pyrazole-4-carbonitrile (10b) 
Pale yellow crystals, 70% yield; mp 160–162 °C; IR (KBr) νmax/cm
−1 2233 (C≡N); 1693 
(C=O), 1610 (C=N); 
1H NMR (DMSO-d6) δ 2.30 (s, 3H, m-CH3), 2.61 (s, 3H, -COCH3), 
7.09–7.52 (m, 9H, ArH); 
13C NMR δ  21.29 (m-CH3), 26.99 (-COCH3), 92.64, 123.58, 
126.37, 126.83, 129.52, 129.62, 129.90, 130.81, 131.12, 138.39, 139.80, 151.01, 151.10, 
192.30 (-COCH3); MS m/z  (%)  301  (M
+, 3.79), 207 (100). Anal. Calcd for  C19H15N3O 
(301.34): C, 75.73; H, 5.02; N, 13.94. Found: C, 75.85; H, 4.89; N, 14.03. 
Synthesis of chalcones 11a–f 
This reaction was carried out by the same procedure described in the synthesis of 
compounds 7a–f using pyrazoles 10a–c instead of 6a–c. 
1,5-Diphenyl-3-[(2E)-3-phenylprop-2-enoyl]-1H-pyrazole-4-carbonitrile (11a) 
White powder, 66% yield; mp 220–222 °C; IR (KBr) νmax/cm
−1 2237 (C≡N); 1664 (C=O), 
1597 (C=N); 
1H NMR (DMSO-d6) δ 7.42–7.98 (m, 17H, ArH); 
13C NMR δ 92.60, 113.73, 
121.65, 126.39, 126.64, 129.53, 129.56 129.69, 129.94, 130.00, 131.16, 131.80, 182.39 (-
C=O); MS m/z (%) 375 (M
+, 0.37), 281 (39.68), 207 (100), 91 (37.51), 73 (79.69). Anal. 
Calcd for C25H17N3O (375.42): C, 79.98; H, 4.56; N, 11.19. Found: C, 80.07; H, 4.58; N, 
11.08. 
3-[(2E)-3-(4-Methoxyphenyl)prop-2-enoyl]-1,5-diphenyl-1H-pyrazole-4-carbonitrile (11b) 
Pale yellow powder, 60% yield; mp 209–211 °C; IR (KBr) νmax/cm
−1 2235 (C≡N); 1667 
(C=O), 1595 (C=N); 
1H NMR (DMSO-d6) δ 3.82 (s, 3H, -OCH3), 7.02 (d, 2H, J = 8.8 Hz, 
ArH), 7.41–7.52 (m, 11H, ArH), 7.6-7.95 (m, 3H, ArH); 
13C NMR δ 56.01 (-OCH3), 93.62, 
113.83, 115.18, 119.04, 126.65, 129.52, 129.93, 130.00, 130.18, 131.62, 138.54, 145.52, 
151.17, 151.65, 162.42, 182.19 (-C=O); MS m/z (%) 406 (M
++1, 0.22), 272 (74.44), 207 
(100), 73 (36.91). Anal. Calcd for C26H19N3O2 (405.45): C, 77.02; H, 4.72; N, 10.36. Found: 
C, 77.17; H, 4.67; N, 10.28. 
1-(3-Methylphenyl)-5-phenyl-3-[(2E)-3-phenylprop-2-enoyl]-1H-pyrazole-4-carbonitrile 
(11c) 
Pale yellow powder, 69% yield; mp 181–183 °C; IR (KBr) νmax/cm
−1 2234 (C≡N); 1663 
(C=O), 1602 (C=N); 
1H NMR (DMSO-d6) δ 2.32 (s, 3H, m-CH3), 7.16-7.53 (m, 13H, ArH), 
7.80-7.98 (m, 3H, ArH); 
13C NMR δ 21.32 (m-CH3), 93.62, 113.75, 121.63, 123.71, 126.41, 
127.00, 129.11, 129.50, 129.58, 129.69, 129.97, 130.84, 131.80, 134.66, 138.47, 139.78, 
145.49, 151.21, 151.36, 182.37 (-C=O); MS m/z  (%)  389  (M
+, 5.28), 207 (100). Anal. 
Calcd for C26H19N3O (389.45): C, 80.18; H, 4.92; N, 10.79. Found: C, 80.31; H, 5.08; N, 
10.74. 
3-[(2E)-3-(4-Methoxyphenyl)prop-2-enoyl]-1-(3-methylphenyl)-5-phenyl-1H-pyrazole-
4-carbonitrile (11d) 
Pale yellow powder, 58% yield; mp 170–172 °C; IR (KBr) νmax/cm
−1 2234 (C≡N); 1667 
(C=O), 1598 (C=N); 
1H NMR (DMSO-d6) δ 2.32 (s, 3H, m-CH3), 3.83 (s, 3H, -OCH3), 7.01–
7.94 (m, 15H, ArH); 
13C NMR δ 21.32 (m-CH3), 56.01 (-OCH3), 93.55, 113.84, 115.18, 
123.71, 126.47, 127.01, 127.32, 129.50, 129.59, 129.96, 130.80, 131.10, 131.62, 138.49, 
139.76, 145.48, 151.11, 151.60, 162.43, 182.18 (-C=O); MS m/z (%) 419 (M
+, 6.37), 207   Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones …519 
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(100). Anal. Calcd for C27H21N3O2 (419.47): C, 77.31; H, 5.05; N, 10.02. Found: C, 77.22; 
H, 4.93; N, 9.95. 
1-(4-Methylphenyl)-5-phenyl-3-[(2E)-3-phenylprop-2-enoyl]-1H-pyrazole-4-carbonitrile 
(11e). 
Pale yellow powder, 64% yield; mp 262–264 °C; IR (KBr) νmax/cm
−1 2236 (C≡N); 1668 
(C=O), 1597 (C=N); 
1H NMR (DMSO-d6) δ 2.35 (s, 3H, p-CH3), 7.28–7.51 (m, 12H, ArH), 
7.79–7.98 (m, 4H, ArH); 
13C NMR δ 21.25 (p-CH3), 93.60, 113.83, 115.46, 121.58 124.65, 
126.41, 127.00, 129.53, 129.69, 129.93, 129.99, 130.33, 131.90, 131.80, 134.12, 139.84, 
146.50, 147.69, 151.20, 182.20 (-C=O); MS m/z  (%)  389  (M
+, 9.65), 207 (200). Anal. 
Calcd for C26H19N3O (389.45): C, 80.18; H, 4.92; N, 10.79. Found: C, 80.34; H, 4.98; N, 
10.85. 
3-[(2E)-3-(4-Methoxyphenyl)prop-2-enoyl]-1-(4-methylphenyl)-5-phenyl-1H-pyrazole-
4-carbonitrile (11f) [38, 39] 
Pale yellow crystals, 66% yield; mp 215–217 °C; IR (KBr) νmax/cm
−1 2237 (C≡N); 1662 
(C=O), 1589 (C=N); 
1H NMR (DMSO-d6) δ (s, 3H, p-CH3), 3.83 (s, 3H, -OCH3), 7,03 (d, 
2H, J = 9.16 Hz, ArH), 7.28–7.50 (m, 9H, ArH), 7.65–7.95 (m, 4H, ArH); 
13C NMR δ 21.25 
(p-CH3), 56.02 (-OCH3), 93.60, 113.84, 115.18, 119.13, 126.41, 126.52, 127.33, 129.51, 
129.98, 130.31, 131.60, 136.16, 139.93, 145.48, 151.09, 162.42, 182.21 (-C=O); MS m/z 
(%) 419 (M
+, 4.24), 207 (100). Anal. Calcd for C27H21N3O2 (419.47): C, 77.31; H, 5.05; N, 
10.02. Found: C, 77.40; H, 4.97; N, 10.16. 
Pharmacology 
Anti-inflammatory Activity 
Adult albino rats of both sexes weighing 120–150 g were obtained from animal house 
laboratory of Nile Company, Cairo, Egypt and acclimatized for 1 week in the animal facility 
that has 12 h light/dark cycles with the temperature controlled at 21–23 °C. Normal rat 
chow and water were made available. The tested compounds and the reference standards 
were completely dissolved in DMSO. The administered oral dose of the tested compounds 
was 10 mg/kg body weight with analogy of a reported procedure. Ninety rats were divided 
into 15 groups each of six animals. All rats were deprived from food and water for 18 h 
before the experiment and were injected orally by 5 mL water to avoid fluid variation during 
the process of edema. Two groups received the reference standards; 12 groups received 
the tested compounds dissolved in DMSO and one group left as negative control group 
which given 0.2 mL DMSO by oral tube. Indomethacin was obtained from Nile Company 
for Pharmaceuticals and Chemical Industries, Cairo, Egypt and meloxicam was obtained 
from Memphis Company for Pharmaceuticals and Chemical Industries, Cairo, Egypt. The 
tested compounds and meloxicam were given by oral route at doses of 10 mg/kg body 
weight while indomethacin was given by oral rout at 5 mg/kg body weight. This dose of 
indomethacin was considered as a positive control for experiments with any new chemical 
entity  [40]. Then, sublunary of 0.1 mL of 2% carrageenan sodium (Sigma, USA) was 
injected in the right hind paw. The volume of the paw was measured immediately after 
injection and after administration of the compounds at time intervals 3 and 6 h by using 
Dial micrometer model (120-1206) Baty, Sussex, England). The results were expressed as 
volume of edema at each time interval, percentage inhibition of edema volume at each 
time with respect to control and potency which was calculated compared to indomethacin.  520  E. Nassar et al.:   
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Ulcerogenic effects 
Ulcerogenic activity of meloxicam, indomethacin and tested compounds were studied in 
Albino rats of wistar strain weighing 150–200 g of either sex and divided into seven groups 
each of six animals. The first group served as control group treated with 0.2 mL DMSO. 
Indomethacin was given by a dose of 5 mg/kg/day while the dose of meloxicam and other 
tested compounds was 10 mg/kg/day. All groups were treated for three consecutive days 
by oral tube. During three days of dosage treatment, the animals were starved for 18 h but 
water was provided ad libitum. Food was allowed 2 hours post administration of the drugs. 
Two hours following the last doses, rats were sacrificed. The stomach of each rat were 
removed, opened along the greater curvature, rinsed with 0.9% sodium chloride (isotonic 
solution) and stretched by pins on a cork  board.  The lesions in gastric mucosa were 
determined by using stereoscopic microscope.  Hemorrhagic lesions were evaluated by 
scores: 0.0, Normal (no injury, bleeding and latent injury); 0.5, Latent injury or widespread 
bleeding; 1.0, Slight injury (2 to 3 dotted lines); 2.0, Severe injury (5-6 dotted injuries); 3.0, 
Very severe injury (several continuous lined injuries) and 4.0, Widespread lined injury or 
widened injury [33]. 
Statistics 
In anti-inﬂammatory study, data are expressed as value ± SEM. Results of carrageenan-
induced paw edema experiments are also expressed as percentage of change from 
control (pre-drug) values. Differences between vehicle control and treatment groups were 
tested using one-way ANOVA followed by multiple comparisons by the Bonferroni’s test. In 
ulcerogenic study, Data are presented as mean ± SD and were subjected to one way 
ANOVA, followed by multiple comparisons by the Bonferroni’s test. 
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